These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37088604)

  • 1. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
    Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
    Jeong HS; Chun BC
    PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Phillips A; Jiang Y; Walsh D; Andrews N; Artama M; Clothier H; Cullen L; Deng L; Escolano S; Gentile A; Gidding G; Giglio N; Junker T; Huang W; Janjua N; Kwong J; Li J; Nasreen S; Naus M; Naveed Z; Pillsbury A; Stowe J; Vo T; Buttery J; Petousis-Harris H; Black S; Hviid A
    Vaccine; 2023 Oct; 41(42):6227-6238. PubMed ID: 37673715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
    BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Clothier HJ; Shetty AN; Mesfin Y; Mackie M; Pearce C; Buttery JP
    Vaccine; 2024 Feb; 42(5):1108-1115. PubMed ID: 38262811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.
    Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC
    Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
    Glover C; Deng L; Larter C; Brogan C; Richardson O; Huang YA; Kay E; Macartney K; Wood N
    Commun Dis Intell (2018); 2024 Jun; 48():. PubMed ID: 38926650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Willame C; Dodd C; Durán CE; Elbers R; Gini R; Bartolini C; Paoletti O; Wang L; Ehrenstein V; Kahlert J; Haug U; Schink T; Diez-Domingo J; Mira-Iglesias A; Carreras JJ; Vergara-Hernández C; Giaquinto C; Barbieri E; Stona L; Huerta C; Martín-Pérez M; García-Poza P; de Burgos A; Martínez-González M; Bryant V; Villalobos F; Pallejà-Millán M; Aragón M; Carreras JJ; Souverein P; Thurin NH; Weibel D; Klungel OH; Sturkenboom M
    Vaccine; 2023 Jan; 41(1):251-262. PubMed ID: 36446653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring.
    Abara WE; Gee J; Delorey M; Tun Y; Mu Y; Shay DK; Shimabukuro T
    J Infect Dis; 2022 May; 225(9):1569-1574. PubMed ID: 34958099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
    Choe YJ; Ahn YH; Gwak E; Jo E; Kim J; Choe SA
    Pediatr Nephrol; 2024 Feb; 39(2):625-629. PubMed ID: 37880380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following HPV vaccination: 11 years of surveillance in Australia.
    Phillips A; Hickie M; Totterdell J; Brotherton J; Dey A; Hill R; Snelling T; Macartney K
    Vaccine; 2020 Aug; 38(38):6038-6046. PubMed ID: 32709432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.